Massad LS, Xie X, Minkoff HL, et al. - Researchers examined the appropriateness of the guidelines recommending women to discontinue cervical cancer screening at the age of 65 years for women living with HIV. In the Women’s Interagency HIV Study, a US multisite cohort study launched in October 1994, Papanicolaou testing was performed semi-annually as part of surveillance visits. A total of 3,678 women living with HIV and 1,304 women living without HIV were enrolled in the Women’s Interagency HIV Study; data throughout September 2019 onward were included in the present work study. They assessed 169 eligible women (121 women living with HIV and 48 women living without HIV) contributing to 678.4 person-years of observation after reaching the age of 65 years; 2.2% of these exhibited high-grade cytologic abnormalities. Per findings, the criteria for cervical cancer screening cessation were not met by most women living with HIV and they will need to continue screening over the age of 65 years; however, risks of high-grade squamous lesions among women who meet the criteria for screening cessation were noted to be similar to that noted among women living without HIV and hence they may choose to discontinue.